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1. Introduction 
Fibromyalgia (FM) is a common pain syndrome accompanied by other symptoms such as 
tender spots, decreased pain threshold, fatigue, headache, sleep disturbances, and 
depression. It is a chronic condition characterized by a pattern of vague symptoms that are 
difficult to diagnose and treat. FM is diagnosed according to the classification criteria 
established by the American College of Rheumatology (ACR) (Wolfe et al., 1990) and 
routine laboratory investigations usually yield normal results (Yunus et al., 1981). The 
prevalence of FM in industrialized countries ranges from 0,4% to 4% (it affects at least 5 
million individuals in the United States and 800.000 in Spain) in the population being 11 
time more frequent in women than in men (Lawrence et el., 2008). Its high prevalence makes 
fibromyalgia a major problem in developed countries in the recent years. FM causes work 
absenteeism and has been associated with high medical services utilization cost and 
considerable disability. Furthermore, the use of medications and medical necessities 
increased markedly across many measures once diagnosis was made. It has been estimated 
that annual health service cost of FM patients was twice that of patients with chronic 
widespread pain and pain-free controls. The fact that its diagnostic criteria are only clinical, 
and that its etiopathogenesis has not yet been clarified makes very difficult the study and 
therapeutical approach of the disease. Although the etiology of FM remains unclear, 
evidence suggests that biologic, genetic, and environmental factors are involved.It is 
considered that the changes in the neuronal activity in the central nervous system, abnormal 
metabolism of biogenic amines, immunological disorders and oxidative stress may among 
others factors contribute to the development of the disease. For all these reasons is urgent to 
do more research in the diagnosis, pathophysiology and therapy of FM. 
Fibromyalgia syndrome has been related to disturbances of hypothalamic–pituitary  
axis together with neurotransmission imbalance, involving excitatory amino acids, 
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catecholamines, substance P and serotonin (5-HT) (Russell et al, 1994; Crofford et al, 1996; 
Neeck, 2002). Patient's symptoms may derive from poor stressor modulation, sensitization 
of specific nociceptor neurons and pain threshold diminution in response to multiple 
environmental factors, such as mechanical or emotional trauma, chronic stress or even 
infections. In recent years, new information to our understanding of FM pathophysiology 
has emerged. Some genetic polymorphisms and antibodies have been associated with FM, 
as the serotoninergic system genotype of 5–HTT (Bazzichi et al., 2006a; Tander et al., 2008), 
catechol-O-methytransferase gene polymorphism (Gursoy et al., 2004), D4 dopamine 
receptor exon II repeat polymorphism (Buskila et al., 2004), and antibodies against serotonin 
(Klein et al., 1992; Werle et al., 2001). It has also been postulated alterations in the 
metabolism, transport and reuptake of serotonin (Alnigenis & Barland, 2001; Schwarz et al., 
2002) and substance P (Staud & Spaeth, 2008). Moreover, cytokines homeostasis has been 
considered to play a role in the pathogenesis of FM (Wallace, 2001; Wallace et al., 2006). 
Conversely, several studies have shown mitochondrial dysfunction and high levels of 
oxidative stress markers in FM patients, suggesting that this process may contribute to the 
pathophysiology of this disease. However, whether oxidative stress is the cause or the effect 
in FM is controversial ( Ozgocmen et al, 2006). 
2. Mitochondrial dysfunction in disease and FM 
2.1 About mitochondria 
Mitochondria are dynamic organelles that play a central role in many cellular functions 
including the generation of chemical energy (adenosine triphosphate, ATP), heat, and 
intracellular calcium homeostasis. They are also responsible for the formation of reactive 
oxygen species (ROS) and for triggering the programmed cell death or apoptosis (Turrens, 
2003). The primary metabolic function of mitochondria is oxidative phosphorylation, an 
energy-generating process that couples oxidation of respiratory substrates to the synthesis 
of ATP (Pieczenik & Neustadt, 2007). The mitochondrial respiratory chain (MRC) is 
composed of five multisubunit enzyme complexes. Both the mitochondrial DNA (mtDNA) 
and the nuclear DNA (nDNA) encode for polypeptide components of these complexes. 
Electron transport between MRC complexes I–IV is coupled to the extrusion of protons 
across the inner mitochondrial membrane by proton pump components of the respiratory 
chain. This movement of protons creates an electrochemical gradient (Δψm) across the inner 
mitochondrial membrane. Protons return to the mitochondrial matrix by flowing through 
ATP synthase (complex V), which utilizes the energy thus produced to synthesize ATP from 
adenosine diphosphate (ADP) and inorganic phosphate (Pi). Both the mtDNA and the 
nDNA encode for polypeptide components of these complexes. As a consequence, 
mutations in either genome can cause MRC dysfunction that impairs transport of electrons 
and/or protons and decreases ATP synthesis. Primary or secondary genetic diseases 
affecting MRC or secondary mitochondrial dysfunctions usually affect brain and skeletal 
muscle because of their energy requirements. Besides MRC enzyme complexes, two electron 
carriers, coenzyme Q10 (CoQ) and cytochrome c, are essential for mitochondrial synthesis of 
ATP. CoQ transports electrons from complexes I and II to complex III and is essential for the 
stability of complex III. CoQ is a lipid-soluble component of virtually all cell membranes. It 
is composed of a benzoquinone ring with a polyprenyl side-chain. The number of isoprene 
units is specie specific, e.g. 10 in humans (CoQ10). CoQ also functions as an antioxidant that 
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protects cells both by direct ROS scavenging and by regenerating other antioxidants such as 
vitamins C and E (Turunen et al., 2004). CoQ deficiency impairs oxidative phosphorylation 
and causes clinically heterogeneous mitochondrial diseases named CoQ deficiency 
syndrome. An increasing number of patients with primary inherited CoQ deficiencies are 
being identified (Littarru & Tiano, 2010). These forms are transmitted as autosomal recessive 
traits and respond to CoQ supplementation, making accurate diagnosis of great practical 
importance. CoQ deficiency can be also a secondary consequence of different diseases or by 
treatment with drugs such as statins. Given the critical role of CoQ in mitochondria 
function, it has been suggested that CoQ levels could be a useful biological marker of 
mitochondrial function (Haas et al., 2008). CoQ deficiency induces decreased mitochondrial 
respiratory enzymes activity, reduced expression of mitochondrial proteins involved in 
oxidative phosphorylation, decreased mitochondrial membrane potential, increased 
production of ROS, mitochondrial permeabilization, mitophagy of dysfunctional 
mitochondria, reduced growth rates and cell death (Quinzii et al., 2008; Rodriguez-
Hernandez et al., 2009, Cotan et al, 2011). 
2.1.1 Reactive Oxygen Species (ROS) 
In addition to energy, mitochondrial oxidative phosphorylation also generates ROS. When 
the MRC becomes highly reduced, the excess electrons from complex I or complex III can be 
passed directly to O2 to generate superoxide anion (O2−). Superoxide is transformed to 
hydrogen peroxide (H2O2) by the detoxification enzymes manganese superoxide dismutase 
(MnSOD) or copper/zinc superoxide dismutase (Cu/Zn SOD), and then to water by 
catalase, glutathione peroxidase (GPX) or peroxidredoxin III (PRX III). However, when these 
enzymes cannot convert ROS such as the superoxide radical to water fast enough, oxidative 
damage occurs and accumulates in the mitochondria. If H2O2 encounters a reduced 
transition metal or is mixed with O2−, the H2O2 can be further reduced to hydroxyl radical 
(OH), the most potent oxidizing agent among ROS. Additionally, nitric oxide (NO) is 
produced within the mitochondria by mitochondrial nitric oxide synthase (mtNOS) and also 
freely diffuses into the mitochondria from the cytosol. NO reacts with O2− to produce 
peroxynitrite (ONOO−). Together, these two radicals as well as others can do great damage 
to mitochondria and other cellular components (Turrens, 2003). 
Under normal physiological conditions, ROS production is highly regulated. However, if 
the respiratory chain is inhibited, or key mitochondrial components, such as CoQ, are 
deficient, then, electrons accumulate on the MRC carriers, greatly increasing the rate of a 
single electron being transferred to O2 to generate O2−. An excessive mitochondrial ROS 
production can exceed the cellular antioxidant defense and the cumulative damage can 
ultimately destroy the cell by necrosis or apoptosis. 
2.1.2 Selective degradation of mitochondria: Mitophagy 
Degradation of excess or dysfunctional organelles is one of the major problems that eukaryotes 
face to maintain cell integrity and to adapt cellular activities to environmental changes. To 
solve this fundamental issue, cells utilize autophagy, which is a self-eating system that 
generates double-membrane vesicles called autophagosomes, sequesters cytoplasmic 
components as cargoes, and transports them to lysosomes for degradation (Klionsky, 2005). In 
the past decade, more than 30 autophagy-related genes (ATG) required for selective and/or 
nonselective autophagic functions have been identified. Selective autophagy contributes to the 
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control of both quality and quantity of organelles. It is conceivable that mitochondria are the 
primary targets of selective autophagy, because they accumulate oxidative damage due to 
their own by-products, ROS (Bhatia-Kiššová I & Camougrand, 2010). 
Consistent with this idea, autophagy-dependent clearance of dysfunctional mitochondria is 
important for organelle quality control. The term mitophagy refers to the selective removal 
of mitochondria by autophagy. It has been proposed that ROS damage can induce 
mitochondria permeabilization by the opening of permeability transition pores in the 
mitochondrial inner membrane (Kim, 2007). This, in turn, leads to a simultaneous collapse 
of mitochondrial membrane potential and the elimination of dysfunctional mitochondria. 
Consistent with this idea, autophagy-dependent clearance of dysfunctional mitochondria by 
mitophagy is important for organelle quality control and can play a pivotal role in 
mitochondria related diseases (Gottlieb et al, 2010).  
2.2 Mitochondrial dysfunction and disease 
Since the first mitochondrial dysfunction was described in 1962 (Luft et al, 1962), 
biomedicine research has advanced in the understanding of the role that mitochondria play 
in health, disease, and aging. Besides the inherited mitochondrial diseases, a wide range of 
seemingly unrelated disorders, such as schizophrenia, bipolar disease, dementia, 
Alzheimer's disease, epilepsy, migraine headaches, strokes, neuropathic pain, Parkinson's 
disease, ataxia, transient ischemic attack, cardiomyopathy, coronary artery disease, chronic 
fatigue syndrome, retinitis pigmentosa, diabetes, hepatitis C, primary biliary cirrhosis, and 
fibromyalgia (FM), have the common pathophysiological mechanisms of production of 
mitochondrial ROS resulting in mitochondrial dysfunction (Pieczenik & Neustadt, 2007). As 
a consequence of these findings, antioxidant therapies hold promise of improving 
mitochondrial performance in these diseases. Although the underlying characteristic of all 
of them is lack of adequate energy to meet cellular needs, they vary considerably from 
disease to disease and from case to case in their effects on different organ systems, age at 
onset, and rate of progression, even within families whose members have identical genetic 
mutations. No symptom is pathognomonic, and no single organ system is universally 
affected. Although a few syndromes are well-described, any combination of organ 
dysfunctions may occur. However, these diseases most often affect the central and 
peripheral nervous systems, but can affect any organs or tissues, including the muscles, 
liver, kidneys, heart, ears, eyes, and endocrine system (Cohen & Gold, 2001) (Table 1).  
Damage to mitochondria is caused primarily by ROS generated by the mitochondria 
themselves. Within the mitochondria, components that are particularly vulnerable to free 
radicals include lipids, proteins, oxidative phosphorylation enzymes, and mtDNA (Shigenaga 
et al., 1994; Tanaka et al., 1996). Direct damage to mitochondrial proteins decreases their 
affinity for substrates or coenzymes and, thereby, decreases their function (Liu et al., 2002). 
Compounding the problem, once a mitochondrion is damaged, mitochondrial function can be 
further compromised by increasing the cellular requirements for energy repair processes  
(Aw & Jones, 1989). Mitochondrial dysfunction can also result in a feed forward process, 
whereby mitochondrial damage causes additional damage. Generated ROS can be released 
into cytosol and trigger “ROS-induced ROS-release” (RIRR) in neighboring mitochondria. This 
mitochondrion-to-mitochondrion ROS-signaling constitutes a positive feedback mechanism 
for enhanced ROS production potentially leading to significant mitochondrial injury (Zorov  
et al, 2006). 
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Organs Sign and Symptoms 
Brain Developmental delay, mental retardation, autism, dementia, seizures, 
neuropsychiatric disturbances, atypical cerebral palsy, atypical migraines, 
stroke, and stroke-like events 
Ears Sensorineural hearing loss, aminoglycoside sensitivity 
Eyes Optic neuropathy and retinitis pigmentosa 
Heart Cardiac conduction defects (heart blocks), cardiomyopathy 
Kidneys Proximal renal tubular dysfunction (Fanconi syndrome); possible loss of 
protein (amino acids), magnesium, phosphorus, calcium, and other electrolytes 
Liver Hypoglycemia, gluconeogenic defects, nonalcoholic liver failure 
Muscles Hypotonia, weakness, cramping, muscle pain, ptosis, opthalmoplegia 
Nerves Neuropathic pain and weakness (which may be intermittent), acute and 
chronic inflammatory demyelinating polyneuropathy, absent deep tendon 
reflexes, neuropathic gastrointestinal problems (gastroesophageal reflux, 
constipation, bowel pseudoobstruction), fainting, absent or excessive 
sweating, aberrant temperature regulation 
Pancreas Diabetes and exocrine pancreatic failure 
Systemic Failure to gain weight, short stature, fatigue, and respiratory problems 
including intermittent air hunger 
Table 1. Signs and symptoms associated with mitochondrial dysfunction (Cohen & Gold, 
2001). 
Furthermore, ROS have an established role in inflammation. Increased levels of 
Inflammatory mediators such as tumor necrosis factor alpha (TNF-ǂ) and interleukins, have 
been associated with mitochondrial dysfunction and increased ROS generation (Naik & 
Dixit, 2011), and it has been hypothesized that abnormal production of cytokines may play a 
role in the pathogenesis of FM (Wallace et al, 2001). IL-1, IL-6 and IL-8 are dysregulated in 
the syndrome and therapies directed against these cytokines may be of potential importance 
in the management of fibromyalgia (Wallace, 2006). However, different studies with 
conflicting results (Uçeyler et al, 2006; Bazzichi et al, 2007) make necessary more studies to 
better understand the role of cytokines in FM. 
2.3 Mitochondrial dysfunction in FM 
Because the main symptoms in FM (pain, stiffness and fatigue) are located in the muscles, 
muscle biopsies, mostly from the trapezious, have been studied. In most cases, 
mitochondrial morphologic alterations have been found in muscle biopsies from FM 
patients. Histochemical analysis demonstrated type II fiber atrophy and the “moth-eaten” 
appearance of type I fibers. Electron microscopic findings were most impressive, and 
included, subsarcolemmal mitochondrial accumulation (Kalyan-Raman et al., 1984), 
myofibrillarlysis with deposition of glycogen and abnormal mitochondria (Yunus et al., 
1986), low number of mitochondria (Sprott et al., 2004), electrons-dense inclusions and lack 
of inner membrane (Hénriksson et al., 1982), ragged red fibres (Bengtsson et al., 1988), and 
single fiber defects of cytochrome-c-oxidase, the complex IV of oxidative phosphorilation 
(Drewes et al., 1993, Pöngratz & Späth, 1998). The presence of moth-eaten and ragged-red 
fibres indicates uneven distribution and proliferation of mitochondria. Accumulation of 
mitochondria is seen in Gomori trichrome staining, and this gives the ragged appearance. 
www.intechopen.com
 New Insights into Fibromyalgia 
 
82
Mitochondrial proliferation may be a compensatory phenomenon in disorders or 
pathophysiological states affecting oxidative metabolism (Bengtsson, 2002). It is interesting 
to mention that ragged red fibres, subsarcolemmal mitochondrial accumulation and 
alteration in ultrastructure, number and size of mitochondrial are typical defects and 
markers found in genuine mitochondrial diseases (MELAS, MERRF, Kearns-Sayre 
syndrome, Pearson syndrome, Leigh syndrome, etc) (Haas et al., 2008).  
However, red ragged fibers appear to be also related to insufficient blood supply (Heffner & 
Barron, 1978), and abnormal capillary microcirculation in tender points was found in FM 
patients (Lund et al, 1986). Microcirculation in the muscle is controlled by the sympathetic 
nervous system and others local and humoral factors. Therefore, the contribution of the 
vasoconstrictor activity of the sympathetic nervous system that produces local hypoxia in 
muscle and fiber damage should be considered in the pathogenesis of red ragged fibers in FM. 
31P Magnetic Resonance Spectroscopy (MRS) analysis in muscle has provided objective 
evidence for metabolic abnormalities consistent with clinical symptoms of weakness  
and fatigue in patients with FM (Park et al., 1998). The MRS examinations showed 
phosphocreatine (PCr) and ATP concentrations in muscles of FM patients to be 15% below 
normal values during rest and exercise. The reduced levels of PCr and ATP in the patients’ 
muscles correlate with clinical observations regarding weakness and pain during exercise. 
In this study, pain was inversely correlated with ATP and PCr levels. Reduction in ATP 
levels also has been observed in the erythrocytes of FM patients, suggesting that this may be 
a more systemic phenomenon than was previously assumed (Russell et al, 1993).  
Recently, it has also been noted a decrease of ATP levels in platelets from FM patients 
(Bazzichi et al., 2008). Blood platelets represent an easily available and simple peripheral 
model to study bioenergetics alterations in FM. Platelets possess mitochondria, the entire 
pool of enzymes or proteins involved in oxidative energy production and, consequently, 
they are active in ATP turnover (Niu et al, 1996). Moreover, platelets present on their plasma 
membrane either pain/inflammation or neurochemical sites, such as adenosine/monoamine 
receptors and transporters (Marazziti et al, 1999; Martini et al, 2004), enabling the study of 
either neurochemistry or ATP energy metabolism in FM. Some recent have shown a 
significant increase of the platelet peripheral benzodiazepine receptor (PBR) (now named 
traslocator protein, TSPO, (Papadopoulos et al, 2006) together with high plasma levels of the 
pro-inflammatory chemokine interleukine 8 (IL-8), low serum cortisol (Bazzichi et al, 2006a) 
as well as a reduced density and functionality of the platelet serotonin transporter (SERT) 
(Bazzichi et al , 2006b) in FM patients. 
3. Mitochondrial dysfunction, oxidative stress in FM 
In general, oxidative stress could be defined as an imbalance between the presence of high 
levels of ROS and reactive nitrogen species (RNS), and the antioxidative defense 
mechanisms. These toxic molecules are formed via oxidation-reduction reactions and are 
highly reactive since they have an odd number of electrons. ROS generated under 
physiological conditions are essential for life, as they are involved in bactericidal activity of 
phagocytes, and in signal transduction pathways, regulating cell growth and reduction–
oxidation (redox) status (Davies, 1995). ROS includes free radicals, such as hydroxyl and 
superoxide radicals, and non-radicals, including hydrogen peroxide and singlet oxygen. 
Oxidative stress and generation of free radicals, as primary or secondary event, have been 
related in a great number of diseases. It has been suggested that oxidative stress is linked to 
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both the initiation and the progression of Parkinson´s disease (Zhou et al., 2008), and strong 
evidence exists for early oxidative stress in Huntington´s disease (Stack et al., 2008). 
Moreover, numerous studies demonstrate that different biomarkers of oxidative-stress-
mediated events are elevated in the Alzheimer disease (Praticò, 2008) and renal disease 
(even in early chronic kidney disease) (Cachofeiro et al., 2008). Moreover, oxidative stress is 
believed to aggravate the symptoms of many diseases, including hemolytic anemias (Fibach 
& Rachmilewitz, 2008), amyotrophic lateral sclerosis (Orrell et al., 2008), and metabolic 
syndrome (Whaley-Connell et al., 2011). 
It is known that ROS overproduction induces lipid peroxidation (LP) leading to oxidative 
destruction of polyunsaturated fatty acids, the main structural component of cellular 
membranes, and the production of toxic and reactive aldehyde metabolites such as 
malondialdehyde (MDA) and 4-hydroxynonenal (HNE) (Draper et al., 2000; Esterbauer et 
al., 1991). These highly cytotoxic metabolites, produced in relatively large amounts, can 
diffuse from their site of origin to attack distant targets and form covalent bonds with 
various molecules. Therefore, recognition of LP is of interest, as the deleterious effects of this 
process might be prevented by administration of scavenging systems or antioxidants.  
In recent years, several studies have shown increased level of oxidative stress markers in FM 
suggesting that this process may have a role in the pathophysiology of this disease (Table 2). 
High levels of LP and protein carbonyls are two of the most documented oxidative damage 
markers to be associated with FM.  
 
Author(s) N(FM/Ctl) Sample(s) Parameter 
Akkus et al., 2009 30/30 Plasma Lipid peroxidation 
(LP)/Vitamins 
A,C,E/Beta-Carotene 
Altindag et al., 2006 20/20 Plasma Total Antioxidant Status 
(TAS)
Altindag et al., 2007 42/53 Serum lipid hydroperoxide 
(LOOH)/TAS/ free 
sulfhydryl groups 
Bagis et al., 2005 85/80 Serum LP/Superoxide 
Dismutase (SOD) 
Cordero et al., 2009 40/25 Plasma/BMCs LP/ROS/Protein 
carbonyls/CoQ10 
Cordero et al., 2010 20/10 Plasma/BMCs LP/Superoxide 
Anion/CoQ10 
Cordero et al., 2010 2/2 Skin biosies LP/CoQ10
Chung et al., 2009 48/96 Urine F2 isoprostanes 
Hein et al., 2002 41/46 Serum Pentosidine
Kaufmann et al., 2008 22/22 Neutrophils Hydrogen peroxide 
Nazıroğlu et al., 2010 32/30 Plasma/ Erythrocytes LP/Glutathione 
peroxidase/Vitamins A 
and E
Ozgocmen et al., 2006 30/16 Serum LP/ SOD/Xanthine 
oxidase
Sendur et al., 2009 37/37 Serum Catalase/Glutathione 
Table 2. References about oxidative stress in Fibromyalgia. 
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Thus, high levels of MDA, a final product of LP, and increased level of protein carbonyls, as 
result of protein oxidation have been reported in plasma from FM patients. Furthermore, it 
has been observed that total antioxidant capacity and superoxide dismutase (SOD), catalase 
and glutathione levels are reduced in FM patients.  
Furthermore, increased LP has been described in patients suffering from depression and 
fatigue, two typical symptoms found in FM patients (Bilici et al., 2001; Vecchiet et al., 2003). 
Studies on depression have signaled a possible link between depression and LP (Evans, 
2003), and the peroxidation-reducing effect of different selective serotonin reuptake 
inhibitors in major depression has been demonstrated (Bilici et al., 2001). It has been 
suggested that alterations in phospholipids which are structural components of cell 
membrane in the brain, may induce changes in membrane microviscosity and, 
consequently, in various neurotransmitter systems, which are thought be related to the 
pathology of depression, e.g., serotonin (5-HT), and noradrenaline (Maes et al., 1996; 
Tsutsumi et al., 1988). LP of cell membranes can modify receptor accessibility, dynamics, 
ligand binding and action, and therefore altering neurotransmitter functions (Lenaz, 1987). 
Oxidative stress may also affect the expression of membrane functional proteins and 
receptors, by interfering with intracellular signalling and receptors turnover, including 
serotonergic receptors (Maes et al., 2007).  
The role of oxidative stress in peripheral neuropathic pain, one of the most prominent 
symptoms in FM, was recently also tested by assessing the effects of antioxidants (acetyl-L-
carnitine, alpha-lipoic acid, and vitamin C) on pain behaviour in a rat model of neuropathic 
pain induced by the antineoplastic agent oxaliplatin (Joseph et al., 2008). Each agent, 
administered locally at the site of mechanical nociceptive testing in the skin, markedly 
inhibited the oxaliplatin-induced hyperalgesia. Finally, ROS also appear to contribute to 
hyperalgesia induced by PKCε (Joseph et al., 2010), potentially linking this mitochondrial 
pathway to the hyperalgesic priming model of chronic peripheral pain. Furthermore, ROS 
are known to be implicated in the etiology of pain by inducing peripheral and central 
hyperalgesia (Wang et al., 2004). Superoxide plays a major role in the development of pain 
through direct peripheral sensitization, the release of various cytokines (for example, TNF-
ǂ, IL-1ǃ, and IL-6), the formation of peroxynitrite (ONOO-), and PARP activation (Wang et 
al., 2004). Although, the mechanisms by which increased oxidative stress can affect 
specifically muscle sensitivity remain to be established, it may be that oxidative damage in 
muscles results in lowering the threshold of nociceptors locally, thus producing and altered 
nociception (Fulle et al., 2000). 
In recent works, we have examined mitochondrial bioenergetics and antioxidant defenses in 
Blood mononuclears cells (BMCs) from FM patients. As CoQ deficiency had been suggested 
to be useful as a mitochondrial dysfunction marker, we addressed mitochondrial 
dysfunction in BMCs from FM patients and examined whether mitochondrial disturbance 
could be involved in the pathophysiology of oxidative stress in FM. We analyzed CoQ levels 
in BMCs and plasma from FM patients. We observed an altered distribution of CoQ levels 
between plasma and cells (high levels in plasma and low levels in cells) (Cordero et al., 
2009). We found that CoQ-deficient BMCs in FM patients showed high level of 
mitochondrial ROS production and increased levels of LP. To confirm oxidative stress in 
FM, BMCs of one representative patient were treated with three antioxidants (CoQ, vitamin 
E, and N-acetilcysteine), and mitochondrial ROS production was examined. Both CoQ and 
vitamin E, two well known lipophilic antioxidants, induced a significantly reduction of ROS 
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(Figure 2). These results suggest that ROS were produced in the lipophilic environment of 
mitochondrial membranes, and that CoQ deficiency may be involved in the oxidative stress 
observed in FM. In addition, biochemical analysis of citrate synthase indicated a depletion 
of mitochondrial mass, suggesting selective mitochondrial degradation in BMCs from FM 
patients. These results were confirmed by electron microscopy that clearly showed 
autophagosomes where mitochondria are being degraded (Figure 1). Mitophagy can be 
beneficial for the cells by eliminating dysfunctional mitochondria, but excessive mitophagy 
can promote cell injury and may contribute to the pathophysiology of FM (Cordero et al., 
2010a).  
Control Patient 
 
Fig. 1. Ultrastructure of BMCs from FM patients. Control BMCs is showing mitochondria 
with a typical ultrastructure. Autophagosome with mitochondria (arrows) were present in 
BMCs from a representative FM patient; Bar =1 μm. (Cordero et al., 2010a). 
In general, there is poor correlation between plasma and tissues levels of CoQ, and even 
patients with genetically proven CoQ deficiency may have plasma CoQ levels at a normal 
range. However, there is a positive correlation between the content of CoQ in skeletal 
muscle, dermal fibroblasts and BMCs (Land et al., 2007; Duncan et al., 2005). Furthermore, 
mitochondrial dysfunction and oxidative stress has also been observed in skin biopsies from 
FM patients. The biopsies showed CoQ deficiency, increased level of LP, and a decrease in 
complex II + III and complex IV (Cordero et al., 2010b). Interestingly, it is known that CoQ 
deficiency induces decreased activities of complex II + III, complex III and complex IV 
(Quinzii et al., 2008). Furthermore, fibroblasts from skin of some patients with CoQ 
deficiency syndrome show a higher production of ROS in mitochondria (Quinzii et al., 
2008). Therefore, skin fibroblasts and BMCs can be helpful for biochemical diagnosis of 
mitochondrial defects in FM patients. As is shown in Table 2, most of the studies about 
oxidative stress markers (MDA levels) in FM have used plasma or serum as experimental 
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sample. However, it has to be taken into account that plasma or serum MDA levels depend 
on the balance between MDA formation and its detoxification and can be affected for many 
factors, such as the dilutional effect of plasma, and the renal and/or tissue clearance. 
Therefore, it would be desirable to measure oxidative stress markers in blood cells rather 
than in plasma o serum. On this point, it has recently been reported increased levels of 
hydrogen peroxide in neutrophils from FM patients (Kaufmann et al., 2008). Interesting, 
there are some discrepancies about the correlation between symptoms and LP and oxidative 
stress in FM. Significant correlation has been observed between antioxidants levels in 
plasma and serum, visual analogue scale (VAS) of pain, and morning stiffness (Altindag & 
Celik, 2007; Sendur et al., 2009). However, Bagis et al. found no correlation between VAS of 
pain and LP or SOD in serum (Bagis et al., 2005). On the other hand, Ozgocmen et al. found 
a significant correlation between depression and LP in serum but not between the 
biochemical parameters and clinical measures of pain and fatigue (Ozgocmen et al., 2006). 
This controversy could be ascribed to a methodological problem because LP levels may 
show higher levels and reflect better the degree of oxidative stress if LP measurement is 
performed in cells rather than in plasma or serum. In fact, we have selected 65 FM patients 
and evaluated the association between LP and clinical symptoms (Table 3). 
 
 
 
Fig. 2. Effect of CoQ10 (up) and Vitamin E (down) about mitochondrial ROS production in 
BMCs from FM patients compared to healthy patients. 
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 Patients Control
 
Age (years)  45.8±11 44.3±12
Tender points  15.4±2.8 ?
Duration of disease (years) 10.4±6.4 ?
Sex (males/female) 5/60 5/40
BMI kg/m2 27.4±4.2 23.31±09
VAS Total score 5.9±1.8* 0.5±0.8
FIQ Total score, range 0 - 80 54.5±16* 3±1.6
Pain 7.3±2.2* 0.7±0.3
Fatigue 7.6±1.9* 1.2±0.9
Morning tiredness 6.7±2.2* 1.1±1.0
Stiffnes 5.9±2.3* 0.6±0.1
Anxiety 5.8±2.7* 1±0.9
Depression 5.2±2.7* 1.2±0.8
Beck Depression Inventory 18.5±8.6* 4±1.9
Table 3. Characteristic findings of the FM patients and control group. Values are means ±SD. 
*P<0.001. (Unpublished data).  
We have observed significant correlation between LP levels BMCs or plasma and clinical 
parameters. However, LP levels in BMCs are better associated than LP levels in plasma to 
clinical symptoms in FM (Table 4), (Unpublished data). 
 
 LP in cells 
r
LP in plasma
r
 
VAS  0.584** 0.452** 
FIQ total score  0.823** 0.578** 
 Pain  0.564** 0.410** 
 Fatigue 0.617** 0.311* 
 Morning tiredness 0.574** 0.397** 
 Stiffness  0.669** 0.402** 
 Anxiety  0.591** 0.433** 
 Depression 0.632** 0.561** 
Beck Depression Inventory 0.875** 0.579** 
Table 4. Correlation between LP and clinical findings in FM patients. *P<0.05; **P<0.01.r, 
Pearson's Correlation Coefficient (Unpublished data). 
Alternatively, as mentioned above, it has been observed low levels of SOD in plasma of FM 
patients (Bagis et al., 2005, Ozgocmen et al., 2006). SOD is an enzyme presents in all cells 
that catalyzes the conversion of superoxide free radicals to oxygen and hydrogen peroxide. 
It is the most powerful antioxidant produced by the body and has been used as a marker of 
antioxidant defense (Marklund SL (1990). Therefore, SOD deficiency in FM may account for 
a low protection of cells against ROS damage and support the hypothesis of FM as an 
oxidative disorder. Besides mitochondrial dysfunction many others objective and 
measurable biomarkers has been proposed that may facilitate diagnosis and monitor the 
activity of FM (Dadabhoy et al, 2008).  
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4. Therapeutic implication of mitochondrial dysfunction in fibromyalgia 
An important problem in FM is the moderate effectiveness of pharmacological therapies. In 
general, about half of all treated patients seem to experience a 30% reduction of symptoms, 
suggesting that many patients with fibromyalgia will require additional therapies (Staud, 
2010). But, in most cases, high incidence of secondary effects is induced by pharmacological 
therapy, and many drugs may induce mitochondrial damage (Neustadt & Pieczenik, 2008). 
Mitochondria can be damaged both directly and indirectly by medications. Medications can 
directly inhibit mtDNA transcription of MRC complexes, damage through other 
mechanisms MRC components, and inhibit enzymes required for any of the steps of 
glycolysis and ǃ-oxidation. Indirectly, medications may damage mitochondrial via the 
production of free radicals, by decreasing endogenous antioxidants such as glutathione and 
by depleting the body of nutrients required for the creation or proper function of 
mitochondrial enzymes or MRC complexes. Damage to mitochondria may explain the side 
effects of many medications. Therefore, treatment with these drugs in patients with 
mitochondrial dysfunction could be counterproductive. In this respect, amitriptyline is a 
tricyclic antidepressant frequently recommended in FM treatment. There are evidences to 
support the short-term efficacy of amitriptilyne 25mg/day in FM (Nishishinya et al, 2008). 
However, there is no evidence to support the efficacy of amitriptyline at higher doses or for 
periods longer than 8 weeks. Furthermore, amitriptyline causes a dose-related cytotoxic 
effect in neurons beginning at clinically relevant concentrations by a mechanism dependent 
on mitochondrial depolarization (Lirk et al, 2006). Recently, our group has reported that 
amitriptyline at high doses induced CoQ deficiency and mitochondrial dysfunction in an in 
vitro cellular assay (Cordero et al., 2009). Moreover, CoQ and alpha-tocopherol 
supplementation prevented the cellular damage induced by amitriptyline. This data 
suggests that high dose or long-period of amitriptyline treatment should be done with 
caution monitoring mitochondrial function and, in case of CoQ deficiency, supplementing 
with CoQ could prevent its adverse effects. 
However, since oxidative stress may arise as a consequence of mitochondrial dysfunction or 
interfere with mitochondrial function, reducing oxidative stress emerges as a form of 
mitochondrial medicine that could be beneficial in FM patients. Thus, CoQ, frequently used 
in mitochondrial disease treatment to boost mitochondria function and prevent ROS 
damage (Tiano et al., 2011; Stack et al., 2008; Zhou et al., 2008; Quinzii & Hirano, 2010), 
might be an alternative treatment in FM. 
Beneficial effects of CoQ administration in FM patients have been observed in a previous 
pilot study (Lister, 2002). In this study, Lister et al reported beneficial effects of oral CoQ and 
Gingko Biloba supplementation in FM patients. They observed an important improvement 
in quality-of-life scores that justified the need for a larger scale clinical trial and further 
investigations into the possible mechanism of action of CoQ. In our studies, oral CoQ 
treatment significantly improved clinical symptoms and decrease oxidative stress in several 
cases of FM (Cordero et al., 2011a; Cordero e al., 2011b). Nevertheless, more controlled 
clinical trials are needed to provide data on effectiveness of CoQ in FM.  
CoQ is a potential drug candidate in the treatment of FM for at least two main reasons. First, 
CoQ is a mitochondrial cofactor with the potential to improve mitochondrial function. 
Second, CoQ is a powerful free radical scavenger that can mitigate LP and DNA damage 
caused by oxidative stress (Lenaz G et al, 2007). Thus, CoQ supplementation has been 
proven to be beneficial in patient with muscle pain associated with statin treatment (Caso et 
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al., 2007), and migraine prophylaxis (Sandor et al., 2005). Furthermore, CoQ has shown anti-
inflammatory and anti-nociceptive activity (Jung et al., 2009), regulating inflammatory gene 
expression as proinflammatory cytokine TNF-alpha (Schmelzer et al., 2008) which has been 
demonstrated to have a role in FM (Menzies et al., 2010). 
Other antioxidants treatment has been assayed in FM. Melatonin, the pineal hormone with 
pleiotropic activity is a known powerful antioxidant and anti-inflammatory and increasing 
experimental and clinical evidence shows its beneficial effects against oxidative/nitrosative 
stress status, including that involving mitochondrial dysfunction (Acuña Castroviejo et al., 
2011).Treatment of FM patients with 3 mg melatonin daily for 30 days significantly 
improved the tender point count, severity of pain, global physical assessments, and sleep 
(Citera et al., 2000). Moreover, in a limited number of cases, administration of 6 mg/day 
melatonin to patients with FMS resulted in normal sleep/wake cycles, normal diurnal 
activity, lack of pain, and fatigue and claims significant improvement of the behavioral 
symptoms including lack of depression (Acuna-Castroviejo et al., 2006). Recently, in a 
double-blind, placebo-controlled clinical study was demonstrated that administration of 
melatonin, alone or in a combination with fluoxetine, was effective in the treatment of 
patients with FM (Hussain et al., 2011). The "Myers' cocktail”, an intravenous vitamin-and-
mineral formula (IVMT) for the treatment of a wide range of clinical conditions, which has 
vitamin c as antioxidant, has been assayed also, and most subjects experienced relief as 
compared to baseline, but no statistically significant differences were seen between IVMT 
and placebo (Ali et al., 2009). 
Vitamin D which controls calcium and phosphorus metabolism (Norman et al, 1992) , is also 
a membrane antioxidant (Wiseman H, 1993) whose deficiency has been linked to chronic 
pain, muscle weakness (Straube et al, 2009; Zhang et al, 2010) and fibromyalgia (Armstrong 
et al 2007). Subsequently, studies evaluating the effects of high-dose vitamin D treatment 
have been demonstrated to improve clinical symptoms in FM(Badsha et al 2009). 
One of the most investigated non-pharmacological therapies in the treatment of FM is 
moderate aerobic exercise, which has found some improvement in patients (Stephens et al., 
2008). A long-term combination of aerobic exercise, strengthening and flexibility improves 
psychological health status and health-related quality of life in patients with fibromyalgia 
(Sañudo et al., 2011). Aquatic exercise program also has showed an improvement on 
symptoms an anti-inflammatory effect in FM (Ortega et al., 2010). Interestingly, exercise 
therapies have been shown to provide significant benefits in patients with mitochondrial 
diseases because they induce an increase in mitochondrial biogenesis and an increase of the 
same size, which is proposed as an alternative therapeutic strategy in these conditions 
(Adhihetty et al., 2007; Safdar et al., 2011a). PGC-1ǂ, an important regulator of 
mitochondrial biogenesis via regulating transcription of nuclear-encoded mitochondrial 
genes, is increased by exercise (Safdar et al., 2011b). This may explain to some extent the 
improvement seen in patients with FM. Antioxidant treatment combined with exercise has 
also been shown to modulate oxidative stress markers in FM patients (Nazıroğlu et al, 2010) 
5. Conclusion 
Mitochondria and oxidative stress may play an essential role in the pathophysiology of FM. 
Since oxidative stress may either arise as a consequence of mitochondrial dysfunction or else 
interfere with mitochondrial function, reducing oxidative stress emerges as a form of 
mitochondrial medicine that could be beneficial in FM patients.  
www.intechopen.com
 New Insights into Fibromyalgia 
 
90
Our study supports the hypothesis that CoQ deficiency and mitochondrial dysfunction can 
contribute to cell bioenergetics imbalance, compromising cell functionality in BMCs of FM 
patients. Abnormal BMCs performance can promote oxidative stress and may contribute to 
altered nociception in FM. CoQ deficiency in FM patients, or in a subgroup of them, could 
also be important to initiate CoQ supplementation. Nevertheless, more research is needed to 
establish a primary causation between mitochondrial dysfunction and FM. 
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